Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2012

View Archived Issues

Novel biomarker presented by the National Institute on Drug Abuse

CSL-362 shows efficacy in AML animal models

German researchers patent novel anti-PRL-R antibody

Novel protein kinase B inhibitors presented by German researchers

Merck KGaA discloses new TBK1 and IKK-epsilon inhibitors

Bayer Intellectual Property presents novel CDK inhibitors

Janssen Pharmaceutica prepares novel glucagon receptor antagonists

The University of Dundee synthesizes new D4/5-HT1A receptor ligands

Researchers develop a novel hTSLP+/- xenograft model to study B-ALL

Investigators report results of clinical study testing Wilms tumor protein analogue peptide vaccine

TLS obtains IND clearance for clinical trial protocol based on crowdsourcing

Abexinostat monotherapy shows significant clinical activity in phase II trials

Novo Nordisk provides update on three clinical development programs

Actelion's novel antibiotic advances into phase III development

Novel mRNA-based influenza vaccine presented by CureVac

Genentech unveils an indicator of LRRK2 kinase activity and novel LRRK2 inhibitor

NPS gains FDA approval for Gattex in treatment of adult short bowel syndrome

New administration route approved for bortezomib in Japan

Exjade approved in Europe for iron overload in patients with thalassemia

Celgene presents promising in vitro results for CC-122

FDA approves Varizig for reducing the severity of chickenpox in individuals at high risk

FDA approves Alexza's Adasuve for acute treatment of agitation

Application filed for use of OneDuro Patch as once-daily treatment of chronic pain in Japan

EMA accepts MAA for aripiprazole depot formulation

FDA expands approval of Tamiflu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...